Literature DB >> 9574819

Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes.

Z Zeng1, N W Andrew, B H Arison, D Luffer-Atlas, R W Wang.   

Abstract

1. Ivermectin was extensively metabolized by human liver microsomes to at least 10 metabolites. The structure of many of them (mostly hydroxylated and demethylated) was determined by 1H-NMR and LC/MS. 2. To determine which human cytochrome P450 isoform(s) is responsible for the metabolism of ivermectin, chemical inhibitors including sulphaphenazole, quinidine, furafylline, troleandomycin (TAO) and diethyldithiocarbamate (DDC) were used to evaluate their effect on ivermectin metabolism. TAO, a specific inhibitor of cytochrome P4503A4, was the most potent inhibitor, inhibiting the total metabolism as well as formation of each metabolite. Metabolism was also inhibited by an anti-human cytochrome 3A4 antibody by 90%. 3. When ivermectin was incubated with microsomes from cells expressing CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4 at 4 mg/ml protein concentrations, metabolic activity was only detected with the microsomes containing CYP3A4. The metabolic profile from cDNA-expressed CYP3A4 microsomes was qualitatively similar to that from human liver microsomes. 4. Thus, cytochrome P4503A4 is the predominant isoform responsible for the metabolism of ivermectin by human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574819     DOI: 10.1080/004982598239597

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  33 in total

Review 1.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 2.  The pharmacokinetics and interactions of ivermectin in humans--a mini-review.

Authors:  Aránzazu González Canga; Ana M Sahagún Prieto; M José Diez Liébana; Nélida Fernández Martínez; Matilde Sierra Vega; Juan J García Vieitez
Journal:  AAPS J       Date:  2008-01-25       Impact factor: 4.009

3.  In vitro metabolism of 14C-moxidectin by hepatic microsomes from various species.

Authors:  J Dupuy; E Escudero; C Eeckhoutte; J F Sutra; P Galtier; M Alvinerie
Journal:  Vet Res Commun       Date:  2001-07       Impact factor: 2.459

4.  Pharmacometric Analysis of Tribendimidine Monotherapy and Combination Therapies To Achieve High Cure Rates in Patients with Hookworm Infections.

Authors:  Janneke M Brussee; Anna Neodo; Jessica D Schulz; Jean T Coulibaly; Marc Pfister; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

5.  A sensitive and selective LC-MS/MS method for quantitation of ivermectin in human, mouse and monkey plasma: clinical validation.

Authors:  Yashpal S Chhonker; Liping Ma; Constant Edi; Daryl J Murry
Journal:  Bioanalysis       Date:  2018-10-16       Impact factor: 2.681

6.  In Vitro and In Vivo Drug-Drug Interaction Study of the Effects of Ivermectin and Oxantel Pamoate on Tribendimidine.

Authors:  Anna Neodo; Jessica D Schulz; Jörg Huwyler; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

7.  CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.

Authors:  Matthew G McDonald; Mark J Rieder; Mariko Nakano; Clara K Hsia; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2009-03-18       Impact factor: 4.436

8.  Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep.

Authors:  M B Molento; A Lifschitz; J Sallovitz; C Lanusse; R Prichard
Journal:  Parasitol Res       Date:  2003-11-21       Impact factor: 2.289

Review 9.  Moxidectin and the avermectins: Consanguinity but not identity.

Authors:  Roger Prichard; Cécile Ménez; Anne Lespine
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

10.  Effects of alcohol-induced increase in CYP2E1 content in human liver microsomes on the activity and cooperativity of CYP3A4.

Authors:  Bikash Dangi; Nadezhda Y Davydova; Marc A Maldonado; Armina Abbasi; Nikita E Vavilov; Victor G Zgoda; Dmitri R Davydov
Journal:  Arch Biochem Biophys       Date:  2020-11-13       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.